Medical network on April 17 - April 11, in the first affiliated hospital of zhengzhou university, China's officially launched the first based on the match of pluripotent stem cells differentiation of clinical transplantation research projects. Academician of Chinese academy of sciences Julie chi chow said: "this shows that the level of stem cells and translational research in China has become the world's highest. Later, Parkinson's and dry age-related macular degeneration treatment will open a new chapter!" 

 

Parkinson's disease and macular degeneration routine therapy is difficult 

 

The two clinical research, by the Chinese academy of sciences and the first affiliated hospital of zhengzhou university jointly. In order to realize the stem cell clinical therapy, stem cell institute of zoology, Chinese academy of sciences Beijing library has been done for more than 10 years of preparation. Only source of neural precursor cells in embryonic stem cells in treatment of Parkinson's disease, they have been carried out for 5 years study in monkeys, so far, the experimental data shows that the scheme is safe and effective, found no adverse reactions. 

 

Julie chi chow, director of stem cell research team member,, 46, is the Chinese academy of sciences, vice-chancellor of the university and the deputy director of cas animal research institute. Also served as the Chinese academy of sciences institute of stem cell and regenerative medicine innovation director, director of the state key laboratory of stem cells and reproductive biology, chairman of the international stem cell organization (ISCF) important academic positions, such as stem cell research field has an authoritative position in the world. 

 

Julie chi chow says, our country is the preferred "of human embryonic neural precursor cells from stem cells to treat Parkinson's disease" and "of retinal pigment epithelial cells from human embryonic stem cells to treat dry age-related macular degeneration" conducting clinical research, because these two diseases are multiple and refractory major diseases in the elderly, including Parkinson's disease is the world's second largest neurodegenerative disease, age-related macular degeneration in the elderly blinding factor in important position. Terminal illness is hard to control the disease, the lack of effective treatment methods. 

 

Combining the two stem cell clinical studies and the central plains 

 

The country can develop stem cell clinical research institutions a total of 30, in the national development planning commission and food drug safety administration recently completed for the record of the first eight stem cells in clinical research, chong YiFuYuan become the only one at the same time to undertake two clinical research work of medical institutions, the national spotlight. 

 

Major tasks of science and technology bureau of the Chinese academy of sciences (ring in biological xiao-bo ren said: "it is chong YiFuYuan combining with stem cell team of Chinese academy of sciences, efficient integration, efficient collaboration, opens up a new field of stem cell therapy research, won the state for the record of eight stem cells both in clinical research." 

 

The clinical study of cooperative unit, the first affiliated hospital of zhengzhou university, cerebrovascular disease, head of the hospital dean xu to Ming, director of the physician, chong YiFuYuan is national one of 30 to have an aptitude for stem cell research institutions, rich source, only neurology MenZhenLiang is up to 170000 people a year, the number of hospitalized 12000, nearly 300000 Parkinson's disease in henan province; There are 133 neurology hospital doctor, among them 39 has got high academic title is the national rare with intraoperative magnetic resonance (NMR) one of such advanced medical equipment hospital operating room. 

 

Animals of the Chinese academy of sciences, Beijing stem cell libraries have established more than 200 strains of human embryonic stem cell lines, can meet the demand of han population over 70%. Chong YiFuYuan mainly rely on our own clinical advantages of cooperative research. 

 

Clinical research, source is the premise. On April 11th, after sending the recruit to launch, 5 days for Parkinson's disease for more than 50. 

 

China's stem cell research and transformation has become the world's highest level 

 

"Stem cell transplant is different with before, the clinical research USES is derived from human embryonic stem cells, is through certain technical means, the clinical donate embryos to obtain from the hospital." Julie chi chow says, if can be found in the bone marrow by matching donor cells with the patient, can greatly improve the therapeutic effect of cells. 

 

Julie chi chow, said the first batch of national archival filing embryonic stem cell clinical research projects in China take the lead in starting, embodies the national system layout and important progress in the field of stem cells, shows that China's stem cell research, regulation and clinical transformation has firmly established itself as one of the world. 

 

Over the years, our country in the field of stem cells to the foresight and system layout, gradually clear the direction of innovation in the field of stem cell and transformation path, and through the national health and family planning commission and the state food and drug supervision and management of the administration for the record, in the transformation of encouraging innovation and strengthen supervision. 

 

In the clinical study, millions of functional cells from human embryonic stem cell sources after immune matches will be precisely with the aid of surgical robot transplanted to macular degeneration and Parkinson's disease patients. In the subsequent years of follow-up, the researchers will system evaluation for the safety and efficacy of new treatments. After they get expected results further multicenter trials.